Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay

Arthritis Research and Therapy

Volumn 15, Issue 2, 2013, Pages

  Mahler, Michael ^a   Gascon, Cristina ^a   Patel, Sima ^a   Ceribelli, Angela ^b,c   Fritzler, Marvin J ^d   Swart, Andreas ^e   Chan, Edward K L ^f   Satoh, Minoru ^g  

^a INOVA DIAGNOSTICS INC   (United States)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF CALGARY   (Canada)

^e Center for Rheumatic Diseases   (Germany)

^f UNIVERSITY OF FLORIDA   (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; COMPLEMENTARY DNA; RPP25 PROTEIN; TH TO ANTIGEN; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN; MITOCHONDRIAL RNA-PROCESSING ENDORIBONUCLEASE; MULTIENZYME COMPLEX; RECOMBINANT PROTEIN; RIBONUCLEASE; RIBONUCLEASE P; RPP25 PROTEIN, HUMAN;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DISEASE CONTROL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; OSTEOARTHRITIS; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; AREA UNDER THE CURVE; IMMUNOLOGY; LUMINESCENCE; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AREA UNDER CURVE; AUTOANTIBODIES; AUTOANTIGENS; ENDORIBONUCLEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOPRECIPITATION; LUMINESCENT MEASUREMENTS; MULTIENZYME COMPLEXES; RECOMBINANT PROTEINS; RIBONUCLEASE P; ROC CURVE; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

EID: 84877801356     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4210     Document Type: Article

References (37)

1. Mahler M, Fritzler MJ. Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci 2010, 1183:267-287. 10.1111/j.1749-6632.2009.05127.x, 20146721.
2. Fritzler MJ, Rattner JB, Luft LM, Edworthy SM, Casiano CA, Peebles C, Mahler M. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2011, 10:194-200. 10.1016/j.autrev.2010.09.025, 20933614.
3. Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ. Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?. Autoimmun Rev 2010, 9:756-760. 10.1016/j.autrev.2010.06.005, 20601198.
4. Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007, 6:432-437. 10.1016/j.autrev.2007.01.013, 17643929.
5. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42. 10.1016/j.semarthrit.2005.03.005, 16084222.
6. Ceribelli A, Cavazzana I, Franceschini F, Airo P, Tincani A, Cattaneo R, Pauley BA, Chan EK, Satoh M. Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 2010, 37:2071-2075. 10.3899/jrheum.100316, 20682663.
7. Van Eenennaam H, Vogelzangs JH, Lugtenberg D, Van Den Hoogen FH, Van Venrooij WJ, Pruijn GJ. Identity of the RNase MRP- and RNase P-associated Th/To autoantigen. Arthritis Rheum 2002, 46:3266-3272. 10.1002/art.10673, 12483731.
8. Van Eenennaam H, Vogelzangs JH, Bisschops L, Te Boome LC, Seelig HP, Renz M, De Rooij DJ, Brouwer R, Pluk H, Pruijn GJ, Van Venrooij WJ, Van Den Hoogen FH. Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 2002, 130:532-540. 10.1046/j.1365-2249.2002.01991.x, 1906554, 12452846.
9. Okano Y, Medsger TA. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990, 33:1822-1828. 10.1002/art.1780331210, 1701994.
10. Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, Wright TM, Curran-Everett D, West SG, Brown KK. Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006, 33:1600-1605.
11. Wiik AS, Hoier-Madsen M, Forslid J, Charles P, Meyrowitsch J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010, 35:276-290. 10.1016/j.jaut.2010.06.019, 20650611.
12. Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, Ahern MJ, Roberts-Thomson PJ. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012, 15:102-109. 10.1111/j.1756-185X.2011.01688.x, 22324953.
13. Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, Buslau M, Worm M, Blank N, Hein R, Muller-Ladner U, Kuhn A, Sunderkotter C, Juche A, Pfeiffer C, Fiehn C, Sticherling M, Lehmann P, Stadler R, Schulze-Lohoff E, Seitz C, Foeldvari I, Krieg T, Genth E, Hunzelmann N. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011, 13:R172. 10.1186/ar3495, 3308107, 22018289.
14. Kuwana M, Kimura K, Hirakata M, Kawakami Y, Ikeda Y. Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 2002, 61:842-846. 10.1136/ard.61.9.842, 1754228, 12176814.
15. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007, 9:R78. 10.1186/ar2276, 2206383, 17688695.
16. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12:340-354. 10.1016/j.autrev.2012.05.011, 22743034.
17. Guerrier-Takada C, Eder PS, Gopalan V, Altman S. Purification and characterization of Rpp25, an RNA-binding protein subunit of human ribonuclease P. RNA 2002, 8:290-295. 10.1017/S1355838202027954, 1370251, 12003489.
18. Eder PS, Kekuda R, Stolc V, Altman S. Characterization of two scleroderma autoimmune antigens that copurify with human ribonuclease P. Proc Natl Acad Sci USA 1997, 94:1101-1106. 10.1073/pnas.94.4.1101, 19751, 9037013.
19. Villalta D, Imbastaro T, Di Giovanni S, Lauriti C, Gabini M, Turi MC, Bizzaro N. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012, 12:114-120. 10.1016/j.autrev.2012.07.005, 22776784.
20. Bonroy C, Van Praet J, Smith V, Van Steendam K, Mimori T, Deschepper E, Deforce D, Devreese K, De Keyser F. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods 2012, 379:53-60. 10.1016/j.jim.2012.03.001, 22446156.
21. Ceribelli A, Satoh M, Chan EK. A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis. Arthritis Res Ther 2012, 14:R128. 10.1186/ar3858, 3446509, 22643159.
22. Mahler M, Fritzler MJ, Bluthner M. Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res Ther 2005, 7:R19-R29. 10.1186/ar1455, 1064884, 15642139.
23. Mahler M, Radice A, Yang W, Bentow C, Seaman A, Bianchi L, Sinico RA. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta 2012, 413:719-726. 10.1016/j.cca.2012.01.004, 22265712.
24. Satoh M, Vazquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009, 19:219-228. 10.1007/s10165-009-0155-3, 2876095, 19277826.
25. Thompson JA, Bau HH. Microfluidic, bead-based assay: Theory and experiments. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:228-236. 10.1016/j.jchromb.2009.08.050, 2818129, 19766545.
26. Op De Beeck K, Vermeersch P, Verschueren P, Westhovens R, Marien G, Blockmans D, Bossuyt X. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev 2012, 12:137-143. 10.1016/j.autrev.2012.02.013, 22387973.
27. Parker JC, Bunn CC. Sensitivity of the Phadia EliA connective tissue disease screen for less common disease-specific autoantibodies. J Clin Pathol 2011, 64:631-633. 10.1136/jcp.2010.084756, 21220786.
28. Shanmugam VK, Swistowski DR, Saddic N, Wang H, Steen VD. Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis. Clin Rheumatol 2011, 30:1363-1368. 10.1007/s10067-011-1766-6, 21614475.
29. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003, 48:203-209. 10.1002/art.10760, 12528120.
30. Krzyszczak ME, Li Y, Ross SJ, Ceribelli A, Chan EK, Bubb MR, Sobel ES, Reeves WH, Satoh M. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 2011, 30:1333-1339. 10.1007/s10067-011-1751-0, 3629275, 21523365.
31. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007, 19:580-591. 10.1097/BOR.0b013e3282e7d8f9, 17917539.
32. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Goulet JR, Rich E, Grodzicky T, Raymond Y, Senecal JL. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008, 58:3902-3912. 10.1002/art.24038, 19035499.
33. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763. 10.1136/ard.2006.062901, 1954657, 17234652.
34. Mahler M, Maes L, Blockmans D, Westhovens R, Bossuyt X, Riemekasten G, Schneider S, Hiepe F, Swart A, Gurtler I, Egerer K, Fooke M, Fritzler MJ. Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther 2010, 12:R99. 10.1186/ar3029, 2911886, 20487535.
35. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, Muller-Ladner U. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012, 71:1355-1360. 10.1136/annrheumdis-2011-200742, 22615460.
36. Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M, Fritzler MJ. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 2012, 14:R50. 10.1186/ar3763, 3446416, 22394602.
37. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S, Stevens W. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011, 13:R211. 10.1186/ar3544, 3334664, 22189167.